Theerapol Prasertsuntarasai is a Rheumatology/Immunology physician. OpenAlex indexes 9 publications with 205 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5609 114th St
Lubbock, TX 79424
Telephone
806-589-1778Provider last certified this registry record 13 Aug 2021.
Industry payments
30 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202527 payments
- AstraZeneca Pharmaceuticals LPProgram year202514 payments
- ABBVIE INC.Program year202513 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
80.9%TNF inhibitor59%Infliximab52%Golimumab47%Enbrel Sureclick0%Humira(Cf) Pen0%Part D + Part B<11 patientsCD20-directed Cytolytic Antibody20.4%Rituximab100%Part B, office-administered≥49 patients+ 8 more classes in this area
Dermatology
12.7%Corticosteroid12.7%Methylprednisolone acetate98%Methylprednisolone sodium succinate1%Methylprednisolone0%Part D + Part B≥72 patientsMusculoskeletal
4.2%RANK Ligand Inhibitor3.9%Denosumab100%Part B, office-administered≥30 patientsXanthine oxidase inhibitor0.1%Allopurinol69%Febuxostat31%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases
Journal of Allergy and Clinical Immunology
2010 - Successful Experience with Adalimumab in a patient with the Hyperimmunoglobulinemia D and Periodic Fever Syndrome
Journal of Allergy and Clinical Immunology
2008 - T-cell Lymphopenia Associated with Infliximab and Cyclophosphamide
The American Journal of the Medical Sciences
2005 - Mycobacterium avium Complex Olecranon Bursitis in a Patient Treated With Alefacept
Mayo Clinic Proceedings
2005 - Diffuse Large B-Cell Lymphoma Manifesting as Acute Respiratory Distress Syndrome
The American Journal of the Medical Sciences
2004
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”